C
Critical Pressure
Virtual biopharmaceutical company developing products to treat vascular dysfunction and shock
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United Kingdom
- Open positions
- None listed
- Dealroom signal
- 22.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2017 | $13M | $53M | Medicxi | — |
Growth signals
Latest recorded traffic for Critical Pressure is 100 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Medicxi
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Critical Pressure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Critical Pressure’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.